Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Donepezil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 5/20 | 1.00 |
| ▸ | BCHE | P06276 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | FAAH | O00519 | 1/20 | 0.98 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.98 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.98 |
| ▸ | PDE5A | O76074 | 1/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
| ▸ | APP | P05067 | 1/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.98 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.98 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.98 |
| ▸ | DRD4 | P21917 | 1/20 | 0.98 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.98 |
| ▸ | MAOB | P27338 | 1/20 | 0.98 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Donepezil SCHEMBL29424585 | 1.00 | BCHE (1.00) | BCHEACHEKDM4EFAAHABCC4 | |
| Donepezil SCHEMBL4256889 | 1.00 | BCHE (1.00) | BCHEACHEKDM4EFAAHABCC4 | |
| Donepezil SCHEMBL5060933 | 1.00 | BCHE (1.00) | BCHEACHEKDM4EFAAHABCC4 | |
| Donepezil SCHEMBL1815 | 1.00 | BCHE (1.00) | BCHEACHEKDM4EFAAHABCC4 | |
| Donepezil SCHEMBL1559622 | 1.00 | BCHE (1.00) | BCHEACHEKDM4EFAAHABCC4 | |
| Donepezil SCHEMBL1123745 | 0.99 | BCHE (1.00) | BCHEACHEKDM4EFAAHABCC4 | |
| Donepezil SCHEMBL4312618 | 0.99 | BCHE (1.00) | BCHEACHEKDM4EFAAHABCC4 | |
| Donepezil SCHEMBL4315806 | 0.99 | BCHE (1.00) | BCHEACHEKDM4EFAAHABCC4 | |
| Donepezil SCHEMBL8265876 | 0.99 | BCHE (1.00) | BCHEACHEKDM4EFAAHABCC4 | |
| Donepezil SCHEMBL3851203 | 0.99 | BCHE (1.00) | BCHEACHEKDM4EFAAHABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210169864-A1 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | MERZ PHARMA GMBH & CO KGAA (DE) | 2021-06-10 | — | — | US | disclosed |
| US-10369187-B2 | Peptide regulators of JNK family kinases | VANDERBILT UNIVERSITY (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180236026-A1 | PEPTIDE REGULATORS OF JNK FAMILY KINASES | VANDERBILT UNIVERSITY | 2018-08-23 | — | — | US | disclosed |
| US-20160136144-A1 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2016-05-19 | — | — | US | disclosed |
| US-20140371260-A1 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | MERZ PHARMA GMBH & CO. KGAA (GE) | 2014-12-18 | — | — | US | disclosed |
| US-8802143-B2 | Method for treating neurodegenerative disorders with oral dosage formulation containing both immediate-release and sustained-release drugs | CENTER LABORATORIES, INC. (TW) | 2014-08-12 | — | — | US | disclosed |
| EP-2260839-A2 | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors | Merz Pharma GmbH & Co. KGaA (DE) | 2010-12-15 | — | — | EP | disclosed |
| US-20100227852-A1 | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors | MERZ PHARMA GMBH & CO. KGAA (DE) | 2010-09-09 | — | — | US | disclosed |
| US-20090124659-A1 | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase and inhibitors | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-05-14 | — | — | US | disclosed |
| EP-1732530-A1 | 1-AMINOVYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF AGITATION AND OTHER BEHAVIORAL DISORDERS, ESPECIALLY THOSE ASSOCIATED WITH ALZHEIMER'S DISEASE | Merz Pharma GmbH & Co.KGaA (DE) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005084655-A1 | 1-AMINOCYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF AGITATION AND OTHER BEHAVIORAL DISORDERS, ESPECIALLY THOSE ASSOCIATED WITH ALZHEIMER’S DISEASE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2005-09-15 | — | — | WO | disclosed |
| US-20050203191-A1 | 1-Aminocyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer's disease | FOREST LABORATORIES, INC. (US) | 2005-09-15 | — | — | US | disclosed |
| US-20040087658-A1 | Synergistic mixture; Alzheimer's disease therapy | MERZ PHARMA GMBH & CO. KGAA (DE) | 2004-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371260-A1 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | ACHE, BACE1, CHRNE | ACHE 1/4885BCHE 4/4885KDM4E 1797/4885 |
| US-20050203191-A1 | 1-Aminocyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer's disease | ACHE, PNMT, APH1A | ACHE 1/4885BCHE 12/4885KDM4E 509/4885 |
| US-20100227852-A1 | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors | ACHE, BACE1, CHRNE | ACHE 1/4885BCHE 4/4885KDM4E 1797/4885 |
| US-20160136144-A1 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | ACHE, PSEN1, BCHE | ACHE 1/4885BCHE 3/4885KDM4E 858/4885 |
| US-20210169864-A1 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | ACHE, PSEN1, BCHE | ACHE 1/4885BCHE 3/4885KDM4E 858/4885 |
| US-20090124659-A1 | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase and inhibitors | ACHE, BACE1, BCHE | ACHE 1/4885BCHE 3/4885KDM4E 1489/4885 |
| US-20040087658-A1 | Synergistic mixture; Alzheimer's disease therapy | ACHE, BACE1, CHRNA5 | ACHE 1/4885BCHE 8/4885KDM4E 3278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.